As of December 31, 2025, the Company’s significant operating subsidiaries were as follows: | | | | | | | | | | | | | | | | | | | | | | | | | | | | Name of Company | | Place of Incorporation | | Date of Incorporation | | Percentage of Ownership | | Principal Activities | | Zai Lab (Hong Kong) Limited | | Hong Kong | | April 29, 2013 | | 100% | | Operating company for business development and R&D activities and commercialization of innovative medicines and device | | Zai Lab (Shanghai) Co., Ltd. | | Mainland China | | January 6, 2014 | | 100% | | Development and commercialization of innovative medicines and devices | | Zai Lab (AUST) Pty. Ltd. | | Australia | | December 10, 2014 | | 100% | | Clinical trial activities | | Zai Lab (Suzhou) Co., Ltd. | | Mainland China | | November 30, 2015 | | 100% | | Development and commercialization of innovative medicines | | Zai Biopharmaceutical (Suzhou) Co., Ltd. | | Mainland China | | June 15, 2017 | | 100% | | Development and commercialization of innovative medicines | | Zai Lab (US) LLC | | United States | | April 21, 2017 | | 100% | | Operating company for business development, R&D activities and certain business activities, including legal, compliance and communication functions of the Company | | Zai Lab International Trading (Shanghai) Co., Ltd. | | Mainland China | | November 6, 2019 | | 100% | | Commercialization of innovative medicines and devices | | Zai Auto Immune (Hong Kong) Limited | | Hong Kong | | November 4, 2020 | | 100% | | Operating company for business development and R&D activities | | Zai Lab (Taiwan) Limited | | Taiwan | | December 10, 2020 | | 100% | | Commercialization of innovative medicines and devices | | Zai Lab Trading (Suzhou) Co., Ltd. | | Mainland China | | October 27, 2020 | | 100% | | Commercialization of innovative medicines |
|